stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Beneish M-score
Neurocrine Biosciences, Inc.'s Beneish M-score for fiscal 2025 is −2.64; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −2.64 | (0.41) |
| FY2024 | −2.23 | (0.56) |
| FY2023 | −1.68 | 0.47 |
| FY2022 | −2.15 | 0.45 |
| FY2021 | −2.60 | (1.05) |
| FY2020 | −1.55 | 0.20 |
| FY2019 | −1.75 | (0.23) |
| FY2018 | −1.52 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 1.18 | — | 1.09 | |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 0.85 | — | 0.34 | |
| Sales growth index | 1.21 | — | 1.08 | |
| Depreciation index | 0.07 | — | 0.01 | |
| SG&A index | 0.95 | — | −0.16 | |
| Total accruals to total assets | (0.07) | — | −0.31 | |
| Leverage index | 1.18 | — | −0.38 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −2.64 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| VTRS Viatris Inc. compare | −3.3× |
| ALKS Alkermes plc compare | −3.3× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | −3.2× |
| ELAN Elanco Animal Health Incorporated compare | −2.7× |
| NBIX Neurocrine Biosciences, Inc. | −2.6× |
| HLN Haleon PLC Sponsored ADR compare | −2.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | −2.6× |
| ZTS Zoetis Inc. compare | −2.4× |
| UTHR United Therapeutics Corporation compare | −2.3× |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement